AusCann cannabinoid medicines one step closer to market

AusCann cannabinoid medicines one step closer to market

AusCann's (ASX: AC8) long awaited medical cannabis product is on its way to pharmacy shelves following the completion of an important medical trial.

The listed cannabis company has now announced a successful pilot study of an optimal final dose form for its cannabinoid medicines.

This clinical study has been ongoing for the last 10 months, with the company hoping its product will solve the stability problem facing medical cannabis products currently on the market.

With the trial completed, AusCann now hopes its first proprietary medicines will be released to the market in the first half of 2019.

The Australian group has been working closely with experts in the legal-weed capital of the US, Colorado, to develop modelling and laboratory scale proof of concept work of the new drug.

The new cannabidiol medicine is different from current medical cannabis products on the market. Medical grade cannabis is currently administered via oral liquids, liquid sprays, hard or soft-shell gelatin capsules, or purely inhaled from the dried cannabis material.

AusCann says it has developed a "unique" oral dose form which "provides consistent and stable dosages of the active cannabinoids with reliable bioavailability".

The pharmaceutical company has lodged a patent in respect to the drug it has developed.

AusCann managing director Elaine Darby says the new product is like nothing else on the market.

"AusCann has developed something truly unique in the world of cannabinoid medicines," says Elaine.

"Delivery of consistent and stable products has been an issue that plagues the cannabis medicine industry. The new hard capsule will be a game changer for doctors and patients as it is easy to use and will give consistent treatment outcomes every time. We are thrilled with the success of this study and look forward to releasing these new pharmaceuticals next year."

In July 2018, AusCann announced it had raised $33.4 million to fund its research and development phase. The company says this money raised will now go towards releasing the product to the market in 2019.

AusCann has also earmarked the funds for several key developments including clinical studies, expansion of manufacturing facilities, establishment of a new facility in Chile and crucial R&D into cannabinoid pharmaceuticals.

Shares in AusCann are up 10.43 per cent to $0.90 per share at 10.04am AEST.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Business success comes from thinking inside the box for TAXIBOX founder
Partner Content
On a first glance, the world of storage solutions might not seem particularly exciting ...
TAXIBOX
Advertisement

Related Stories

Space beer, crops and embryos: Saber unveils plans for International Space Station mission

Space beer, crops and embryos: Saber unveils plans for International Space Station mission

Australian space engineering company Saber Astronautics has today u...

Will philosophy and ‘counterfactuals’ help us unlock the mysteries of AI?

Will philosophy and ‘counterfactuals’ help us unlock the mysteries of AI?

Artificial intelligence is increasingly being rolled out all around...

ACCC launches probe into misleading social media influencer posts

ACCC launches probe into misleading social media influencer posts

Australia's consumer watchdog is cracking down on social media ...

Takeover talks reignited between Tyro and Potentia Capital

Takeover talks reignited between Tyro and Potentia Capital

Talks of a potential takeover are back on between Sydney-based Tyro...